MIPSS70+ v2.0 (Mutation/Karyotype-Enhanced IPSS for Primary Myelofibrosis)

Stratifies overall-survival risk in primary myelofibrosis using the karyotype- and mutation-enhanced MIPSS70+ version 2.0; requires molecular (HMR, CALR) and cytogenetic data, applies the sex-adjusted anemia definition, and was validated in patients age ≤70 — it is a prognostic classifier for PMF, not a treatment directive or a substitute for full pathologic/genetic workup.

Sex (selects the sex-adjusted anemia thresholds)

Hemoglobin (g/dL, NOT g/L)

Circulating (peripheral-blood) blasts (%)

Constitutional symptoms (weight loss / night sweats / fever)

Karyotype risk category (revised Tefferi 2018 cytogenetic risk)

High-molecular-risk (HMR) mutation count (HMR = ASXL1, SRSF2, EZH2, IDH1, IDH2, U2AF1 Q157 only)

Type 1 / type 1-like CALR mutation (REVERSED: ABSENCE scores +2)